SLC5A2 and myocardial infarction: Besides favorable actions on the heart by treating diabetes [1,26], SGLT2 inhibitors also protected normoglycemic animals in heart failure models [7,8,10,11], myocardial infarction [13,14], and occlusion/reperfusion models [12].